Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Apr;12(2):144-153.
doi: 10.4103/1735-5362.202453.

Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran

Mohammadreza Amirsadri  1 , Mohammad Javad Sedighi  1
Affiliations

Cost-effectiveness evaluation of aspirin in primary prevention of myocardial infarction amongst males with average cardiovascular risk in Iran

Mohammadreza Amirsadri et al. Res Pharm Sci. 2017 Apr.

Abstract

Aspirin is one of the certified medicines commonly used for the secondary prevention of myocardial infarction (MI). Aspirin side effects and gastrointestinal bleeding, in particular, have arisen debates on its use for the primary prevention of MI. The present research evaluates the cost-effectiveness of the use of aspirin in the primary prevention of MI among Iranian men with average cardiovascular disease (CVD) risk, using Markov modeling technique. The incremental cost-effectiveness ratios (ICERs) estimated to be 864 USA dollars (USD) per quality-adjusted life years (QALY) gained and 782 USD per life years gained (LYG) for each patient in the base-case scenario (public tariffs and no discounting). This research proves cost-effectiveness of the use of aspirin in the primary prevention of MI in targeted population, since the assessed ICERs are quite under the recommended threshold by WHO which is one gross domestic product (GDP) per capita ($5315.1 for Iran in 2015).

Keywords: Aspirin; Cardiovascular diseases; Cost-effectiveness; Markov chain; Primary prevention.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
The semi-Markov model. (GIB) gastrointestinal bleeding; (MI) myocardial infarction; other death, death because of causes except MI and GIB.
Fig. 2
Fig. 2
One-way sensitivity analysis of incremental cost/LYG (public tariffs). (LYG) life years gained.
Fig. 3
Fig. 3
One-way sensitivity analysis of incremental cost/QALY (public tariffs). (QALY) quality-adjusted-life-years.
Fig. 4
Fig. 4
Probabilistic sensitivity analyses scatter plot of incremental cost/LYG ratio (public tariffs). (LYG) life years gained.
Fig. 5
Fig. 5
Probabilistic sensitivity analyses scatter plot of Incremental cost/QALY ratio (public tariffs). (QALY) quality-adjusted life years.
Fig. 6
Fig. 6
Cost-effectiveness acceptability curve plot of aspirin therapy versus no medication.
See this image and copyright information in PMC

References

    1. Murray CJL, Lopez AD. The global burden of disease: a comprehensive assessment of mortality & morbidity from diseases, injuries and risk factors in 1990 & projected to 2020. Cambridge, Mass: Harvard University Press; 1996. p. 1501.
    1. Colin D. Mathers, Dejan Loncar. Updated projections of global mortality and burden of disease, 2002-2030. PLoS Med. 3(11):e442. doi:10.1371/journal.pmed.0030442. - PMC - PubMed
    1. Beyranvand MR LA, Alipour Parsa S, Motamedi MR, Kolahi AA. The quality of life after first acute myocardial infarction. Pajohandeh. 2011;15(6):264–272.
    1. Salim Yusuf, Steven Hawken, Stephanie Ôunpuu, Tony Dans, Alvaro Avezum, Fernando Lanas, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–952. - PubMed
    1. Nichols M, Townsend N, Scarborough P, Rayner M. Cardiovascular disease in Europe 2014: epidemiological update. Eur Heart J. 2014;35:2950–2959. - PubMed